Trial Profile
A study evaluating pretreatment features and risk of death BRAF-positive metastatic melanoma patients treated with vemurafenib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jun 2017
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 14 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology